Real World Study of Linperlisib for Lymphoma Treatment (MA-LYM-RWS-001)

Shanghai Jiao Tong University

Status: Not yet enrolling

Conditions: Focus on the Lymphoma Including B/T-cell Lymphoma

Treatments: Drug: Linperlisib

Study type: Observational

Funder types: Other

Identifiers

NCT05863871

E20230190

Details and patient eligibility

About

This is a multicenter, non-interventional and observational real-world study to evaluate the efficacy and safety of linperlisib in patients with lymphoma.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥18 years
2. Clinical diagnosis of lymphoma patients
3. Patients signed informed consent, volunteered to join the study, and had the willingness and ability to cooperate with the data collection in this study;
4. The researchers' assessment can use Linperlisib treatment

Exclusion criteria

1. The nature of the study could not be understood or informed consent was not obtained
2. Other ineligible conditions were assessed by the investigator

Trial design

1,000 participants in 1 patient group

all enrolled patients

Description:

All patient who signed the consent form for participation to the study

Treatment:

Drug: Linperlisib